Skip to main content

Effect of Tocilizumab on Bone Outcomes in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

In brief

Tocilizumab shifts bone markers in rheumatoid arthritis, but not bone density

Across eight studies involving 1,221 people with rheumatoid arthritis, tocilizumab lowered two markers of bone breakdown and raised a marker of bone formation. These biochemical changes did not produce measurable gains in hip or spine bone density during follow-up, so whether they translate into stronger bones or fewer fractures remains unknown.

Journal
Endocrine connections (Q2)
Published
12 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Feixue Jiang, Siqi Tang, Zhipeng Cui, Deshi Chen, Zhongyan Shan, Weiping Teng, et al.
PMID
43019449
DOI
10.1530/EC-26-0503

Why clinicians should know about it

  • Picked for Biochemistry (medical) (top studies of the week, 15 November 2026): Meta-analysis assesses bone-turnover biochemical markers

Abstract

BACKGROUND: Tocilizumab (TCZ), an interleukin-6 receptor inhibitor for rheumatoid arthritis (RA), may benefit bone metabolism. This meta-analysis aimed to synthesize the effects of TCZ on bone turnover markers (BTMs) and bone mineral density (BMD). METHODS: Cochrane Library, Embase, PubMed, Scopus, and Web of Science were searched from inception to 23 February 2025. Randomized controlled trials and observational studies comparing TCZ with controls and reporting BTMs or BMD were included. Pooled mean differences (MDs) or standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated. RESULTS: Eight studies involving 1,221 participants were included. TCZ significantly reduced C-terminal telopeptide of type I collagen (CTX-I) (MD = -0.05, 95% CI [-0.08, -0.02], P = 0.001; I2 = 0%) and carboxyterminal telopeptide of type I collagen (ICTP) (MD = -7.19, 95% CI [-12.39, -1.99], P = 0.007; I2 = 97%), and increased procollagen type I N-terminal propeptide (PINP) (SMD = 0.21, 95% CI [0.08, 0.34], P = 0.001; I2 = 0%). The overall effect on osteocalcin (OC) was not significant, whereas RCT subgroup analysis showed a significant increase (MD = 3.83, 95% CI [1.12, 6.54], P = 0.006). No significant improvement in femoral neck BMD or lumbar spine BMD was observed. CONCLUSIONS: TCZ may improve bone metabolism in RA by suppressing bone resorption and promoting bone formation. However, these biochemical changes did not translate into measurable increases in BMD during follow-up. Further long-term studies are warranted to clarify effects on BMD.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.